Rougereau A, Person O, Rougereau G
Int J Vitam Nutr Res. 1987;57(1):25-9.
Using new techniques for micro-determinations of blood fat soluble vitamin concentrations, this study from a large population of cancer patients compared to healthy controls led to the finding, extraction and isolation of an abnormal cholecalciferol derivative the 1-ceto-24-methyl-25-hydroxycholecalciferol. This factor was shown to be present in serum from cancer patients and absent in most normal controls. A double blind study has confirmed the diagnostic value of this new marker of cancer. In the same time, an animal study was performed. The abnormal cholecalciferol derivative, absent in intact rats, was found in the blood of rats transplanted by the Ehrlich carcinoma. The compound, extracted from serum of human cancer patients, injected to transplanted rats significantly decreased their survival time. Injected to untransplanted rats it induced hypocalcemia. The genesis and the possible role of this factor in cancer development are discussed.
本研究采用新技术微量测定血脂溶性维生素浓度，以大量癌症患者为研究对象，并与健康对照进行比较，结果发现、提取并分离出一种异常的胆钙化醇衍生物——1-酮基-24-甲基-25-羟基胆钙化醇。研究表明，该因子存在于癌症患者的血清中，而在大多数正常对照中不存在。一项双盲研究证实了这种新的癌症标志物的诊断价值。同时，进行了一项动物研究。在完整大鼠体内不存在的异常胆钙化醇衍生物，在接种艾氏癌的大鼠血液中被发现。从人类癌症患者血清中提取的该化合物注射到接种肿瘤的大鼠体内，显著缩短了它们的存活时间。注射到未接种肿瘤的大鼠体内则会导致低钙血症。本文讨论了该因子的产生及其在癌症发展中可能发挥的作用。
